Literature DB >> 10719865

Intracerebral clysis in a rat glioma model.

J N Bruce1, A Falavigna, J P Johnson, J S Hall, B D Birch, J T Yoon, E X Wu, R L Fine, A T Parsa.   

Abstract

OBJECTIVE: Intracerebral clysis (ICC) is a new term we use to describe convection-enhanced microinfusion into the brain. This study establishes baseline parameters for preclinical, in vivo, drug investigations using ICC in a rat glioma model.
METHODS: Intracranial pressure was measured, with an intraparenchymal fiber-optic catheter, in male Fischer rats 10, 15, 20, and 25 days after implantation of C6 glioma cells in the right frontal lobe (n = 80) and in control rats without tumor (n = 20), before and during ICC. A 25% albumin solution (100 microl) was infused through an intratumoral catheter at 0.5, 1.0, 2.0, 3.0, and 4.0 microl/min. Infusate distribution was assessed by infusion of fluorescein isothiocyanate-dextran (Mr 20,000), using the aforementioned parameters (n = 36). Brains were sectioned and photographed under ultraviolet light, and distribution was calculated by computer analysis (NIH Image for Macintosh). Safe effective drug distribution was demonstrated by measuring tumor sizes and apoptosis in animals treated with N,N'-bis(2-chloroethyl)-N-nitrosourea via ICC, compared with untreated controls. Magnetic resonance imaging noninvasively confirmed tumor growth before treatment.
RESULTS: Intracranial pressure increased with tumor progression, from 5.5 mm Hg at baseline to 12.95 mm Hg on Day 25 after tumor cell implantation. Intracranial pressure during ICC ranged from 5 to 21 mm Hg and was correlated with increasing infusion volumes and increasing rates of infusion. No toxicity was observed, except at the higher ends of the tumor size and volume ranges. Fluorescein isothiocyanate-dextran distribution was greater with larger infusion volumes (30 microl versus 10 microl, n = 8, P < 0.05). No significant differences in distribution were observed when different infusion rates were compared while the volume was kept constant. At tolerated flow rates, the volumes of distribution were sufficient to promote adequate drug delivery to tumors. N,N'-Bis(2-chloroethyl)-N-nitrosourea treatment resulted in significant decreases in tumor size, compared with untreated controls.
CONCLUSION: The C6 glioma model can be easily modified to study aspects of interstitial delivery via ICC and the application of ICC to the screening of potential antitumor agents for safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719865     DOI: 10.1097/00006123-200003000-00031

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  32 in total

1.  Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump.

Authors:  Adam M Sonabend; R Morgan Stuart; Jonathan Yun; Ted Yanagihara; Hamed Mohajed; Steven Dashnaw; Samuel S Bruce; Truman Brown; Alex Romanov; Manu Sebastian; Fernando Arias-Mendoza; Emilia Bagiella; Peter Canoll; Jeffrey N Bruce
Journal:  Neuro Oncol       Date:  2011-07-12       Impact factor: 12.300

2.  Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy.

Authors:  Wenbo Zhan; Davis Yohanes Arifin; Timothy Ky Lee; Chi-Hwa Wang
Journal:  Pharm Res       Date:  2017-02-02       Impact factor: 4.200

3.  Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents.

Authors:  Michal T Krauze; Ryuta Saito; Charles Noble; Matyas Tamas; John Bringas; John W Park; Mitchel S Berger; Krystof Bankiewicz
Journal:  J Neurosurg       Date:  2005-11       Impact factor: 5.115

4.  Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke.

Authors:  Nsikan Akpan; Esther Serrano-Saiz; Brad E Zacharia; Marc L Otten; Andrew F Ducruet; Scott J Snipas; Wen Liu; Jennifer Velloza; Greg Cohen; Sergeyi A Sosunov; William H Frey; Guy S Salvesen; E Sander Connolly; Carol M Troy
Journal:  J Neurosci       Date:  2011-06-15       Impact factor: 6.167

5.  Compression stiffening of brain and its effect on mechanosensing by glioma cells.

Authors:  Katarzyna Pogoda; LiKang Chin; Penelope C Georges; FitzRoy J Byfield; Robert Bucki; Richard Kim; Michael Weaver; Rebecca G Wells; Cezary Marcinkiewicz; Paul A Janmey
Journal:  New J Phys       Date:  2014-07       Impact factor: 3.729

6.  Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.

Authors:  Yoji Yamashita; Michal T Krauze; Tomohiro Kawaguchi; Charles O Noble; Daryl C Drummond; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

Review 7.  Convection-enhanced drug delivery for glioblastoma: a review.

Authors:  Randy S D'Amico; Manish K Aghi; Michael A Vogelbaum; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

8.  Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model.

Authors:  Randy S D'Amico; Justin A Neira; Jonathan Yun; Nikita G Alexiades; Matei Banu; Zachary K Englander; Benjamin C Kennedy; Timothy H Ung; Robert J Rothrock; Alexander Romanov; Xiaotao Guo; Binsheng Zhao; Adam M Sonabend; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurosurg       Date:  2019-08-02       Impact factor: 5.115

Review 9.  Convection-enhanced delivery for the treatment of pediatric neurologic disorders.

Authors:  Debbie K Song; Russell R Lonser
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

10.  Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children.

Authors:  Richard C E Anderson; Benjamin Kennedy; Candix L Yanes; James Garvin; Michael Needle; Peter Canoll; Neil A Feldstein; Jeffrey N Bruce
Journal:  J Neurosurg Pediatr       Date:  2012-12-14       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.